Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

India CEO Pay: Local Firms Still Way Ahead Of Foreign Peers

Executive Summary

CEOs of top Indian firms continue to earn more than their peers at leading multinational firms operating in the country and experts see limited prospects for a major change in pay structures at foreign firms, at least for now. Scrip brings you a snap-shot of CEO earnings at some leading Indian and foreign firms in 2016-17.

You may also be interested in...



CEO Pay In India: A Mixed Bag But Multiples Versus Employee Earnings Huge

Managing directors/CEOs of foreign firms in India drew higher remuneration in 2019-20 versus the previous year and overall earnings of peers at Indian firms continued to be way higher in general. CEO-to-employee pay ratios remains stark, reaching over 550 in one case.

Pharma CEO Pay Up In India, Ratio Versus Employee Earnings Glaring

Pharma CEOs in India took home higher remuneration in 2017-18, with experts suggesting that the upward trend isn’t entirely unexpected. The huge CEO-to-employee pay ratios – over 600 in one case – isn’t a healthy trend, though.

Scrip 100: Indian CEO pay league table – Local heads beat big pharma bosses

If you thought executives heading large pharma multinational corporations (MNCs) in India were the ones who raked in the cash, then you're not entirely wrong. But would you be surprised to learn that bosses at Indian firms, most of them part of the firm's founding family, are the ones who make the real big bucks?

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC099602

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel